Grace L. Guo, MBBS, Ph.D.
Rutgers University – Ernest Mario School of PharmacyEOHSI – Toxicology
Work EOHSI Room 322 170 Frelinghuysen Rd Piscataway NJ 08854 work
Work Phone: 848-445-8186 (office)work
Work Phone: 848-445-6102 (Lab)work
Work Fax: 732-445-4161workfax
Work Email: email@example.comINTERNET
Website: Dr. Guo’s Bio Page
Dr. Guo is an Associate Professor at the Department Pharmacology and Toxicology in the Ernest Mario School of Pharmacy of Rutgers University. She is an adjunct faculty of the Department of Pharmacology, Toxicology and Therapeutics in School of Medicine at the University of Kanas Medical Center. Dr. Guo obtained her MBBS degree from the West China University of Medical Sciences in 1993 and a PhD degree from the University of Kansas Medical Center in 2001, as well as post-doctoral training at the NCI, NIH in 2004. From 2004-2012, Dr. Guo has served as a faculty at the University of Kansas Medical Center.
Liver is essential for life and liver functions are tightly regulated. Particularly, the impact of intestine on liver homeostasis, function and diseases is significant, but this impact has been less studied. Our group has been focusing on determining the effects of intestine-liver crosstalks on liver metabolism and pathogenesis and the underlying molecular mechanisms, especially following disruption of endogenous homeostasis and exposure to xenobiotic chemicals.
- 2012: Presidential Poster Award, AASLD meeting (2)
- 2011: Presidential Poster Award, AASLD meeting
- 2010: Presidential Poster Award, AASLD meeting
- 2009: Presidential Poster Award, AASLD meeting
- 2009: Post award winner for Annual Liver Center Symposium, University of Kansas Medical Center
- 2007: First place in oral presentation in Annual Cancer Center Symposium, University of Kansas Medical Center
- 2005: BIRCWH/NIH scholar
- Murray, A, Banota, T, Guo, GL, Smith, LC, Meshanni, JA, Lee, J, Kong, B, Abramova, EV, Goedken, M, Gow, AJ et al.. Farnesoid X receptor regulates lung macrophage activation and injury following nitrogen mustard exposure. Toxicol Appl Pharmacol. 2022;454 :116208. doi: 10.1016/j.taap.2022.116208. PubMed PMID:35998709
- Jiang, M, Li, F, Liu, Y, Gu, Z, Zhang, L, Lee, J, He, L, Vatsalya, V, Zhang, HG, Deng, Z et al.. Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation. Hepatology. 2022; :. doi: 10.1002/hep.32608. PubMed PMID:35689610
- Seok, S, Kim, YC, Zhang, Y, Kong, B, Guo, G, Ma, J, Kemper, B, Kemper, JK. Feeding activates FGF15-SHP-TFEB-mediated lipophagy in the gut. EMBO J. 2022;41 (17):e109997. doi: 10.15252/embj.2021109997. PubMed PMID:35686465 PubMed Central PMC9434102
- Zhang, L, Guo, GL. Gut-specific inhibition of PPARα as a novel approach of NAFLD treatment. Hepatology. 2022; :. doi: 10.1002/hep.32592. PubMed PMID:35633082
- Guzman, S, Dragan, M, Kwon, H, de Oliveira, V, Rao, S, Bhatt, V, Kalemba, KM, Shah, A, Rustgi, VK, Wang, H et al.. Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model. J Clin Invest. 2022;132 (10):. doi: 10.1172/JCI145889. PubMed PMID:35349482 PubMed Central PMC9106350
- Ryu, E, Xia, HH, Guo, GL, Zhang, L. Multivariable-adjusted trends in mortality due to alcoholic liver disease among adults in the United States, from 1999-2017. Am J Transl Res. 2022;14 (2):1092-1099. . PubMed PMID:35273712 PubMed Central PMC8902556
- Kong, B, Rizzolo, D, Taylor, RE, Guo, GL. Bile Acid Profiling in Mouse Biofluids and Tissues. Methods Mol Biol. 2022;2455 :305-318. doi: 10.1007/978-1-0716-2128-8_23. PubMed PMID:35213003 PubMed Central PMC8922367
- Memon, N, Lee, CW, Herdt, A, Weinberger, BI, Hegyi, T, Carayannopoulos, MO, Aleksunes, LM, Guo, GL, Griffin, IJ. Suppression of Bile Acid Synthesis in a Preterm Infant Receiving Prolonged Parenteral Nutrition. J Clin Exp Hepatol. ;12 (1):200-203. doi: 10.1016/j.jceh.2021.04.007. PubMed PMID:35068799 PubMed Central PMC8766543
- Rizzolo, D, Kong, B, Taylor, RE, Brinker, A, Goedken, M, Buckley, B, Guo, GL. Bile acid homeostasis in female mice deficient in Cyp7a1 and Cyp27a1. Acta Pharm Sin B. 2021;11 (12):3847-3856. doi: 10.1016/j.apsb.2021.05.023. PubMed PMID:35024311 PubMed Central PMC8727763
- Rizzolo, D, Kong, B, Piekos, S, Chen, L, Zhong, X, Lu, J, Shi, J, Zhu, HJ, Yang, Q, Li, A et al.. Effects of Overexpression of Fibroblast Growth Factor 15/19 on Hepatic Drug Metabolizing Enzymes. Drug Metab Dispos. 2022;50 (4):468-477. doi: 10.1124/dmd.121.000416. PubMed PMID:34965924
Categories: Faculty, Toxicology, Member, Tox Member
Updated 3 months ago.